Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12389920 | 0.84 | CA2 (0.68) | CA2TUBB1ALDH1A1HTTKDM4E | |
| SCHEMBL28385292 | 0.84 | PKM (0.47) | PTGS2CA2PKMALDH1A1LMNA | |
| SCHEMBL2559405 | 0.83 | ATM (0.48) | CA2ALDH1A1KDM4EATMPPARG | |
| SCHEMBL4482868 | 0.83 | HTT (0.54) | PTGS2CA2TUBB1ALDH1A1HTT | |
| SCHEMBL31428 | 0.82 | CA2 (0.71) | PTGS2CA2ALDH1A1HTTKDM4E | |
| SCHEMBL31275634 | 0.82 | CA2 (0.71) | PTGS2CA2ALDH1A1HTTKDM4E | |
| SCHEMBL25000916 | 0.81 | CA2 (0.47) | CA2TUBB1ALDH1A1HTTKDM4E | |
| SCHEMBL12806222 | 0.81 | CA2 (0.47) | CA2TUBB1ALDH1A1HTTKDM4E | |
| SCHEMBL14183053 | 0.81 | PKM (0.45) | PTGS2PKMALDH1A1HTTKDM4E | |
| SCHEMBL5366841 | 0.81 | TTR (0.54) | CA2TUBB1ALDH1A1HTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024039883-A2 | COMPOSITIONS AND METHODS TO TREAT MYELOPROLIFERATIVE DISORDERS AND MYELOPROLIFERATIVE NEOPLASMS | TRANSLATIONAL DRUG DEVELOPMENT LLC (US) | 2024-02-22 | — | — | WO | disclosed |
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230288824-A1 | ELECTROPHOTOGRAPHIC PHOTORECEPTOR, PROCESS CARTRIDGE, AND IMAGE FORMING APPARATUS | FUJIFILM BUSINESS INNOVATION CORP. (JP) | 2023-09-14 | — | — | US | disclosed |
| WO-2023090904-A1 | SMOKING ARTICLE COMPRISING NOVEL FLAVORANT | 주식회사 케이티앤지 | 2023-05-25 | — | — | WO | disclosed |
| WO-2023090898-A1 | SMOKING PRODUCT CONTAINING NOVEL FLAVORING AGENT | 주식회사 케이티앤지 | 2023-05-25 | — | — | WO | disclosed |
| US-20220112176-A1 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2022-04-14 | — | — | US | disclosed |
| WO-2019055590-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-20190077793-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2019-03-14 | — | — | US | disclosed |
| US-20170349566-A1 | AN EFFICIENT PROCESS FOR THE SYNTHESIS OF ALKOXY SUBSTITUTED BENZALDEHYDES | ANTHEA AROMATICS PRIVATE LIMITED (IN) | 2017-12-07 | — | — | US | disclosed |
| US-20170334819-A1 | A MILD CATALYTIC REDUCTION OF C-O BONDS AND C=O BONDS USING A RECYCLABLE CATALYST SYSTEM | ORGANOFUEL SWEDEN AB (SE) | 2017-11-23 | — | — | US | disclosed |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-19 | — | — | US | disclosed |
| US-20090012117-A1 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-01-08 | — | — | US | disclosed |
| US-20080119453-A1 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-05-22 | — | — | US | disclosed |
| US-20080113990-A1 | Biphenyl derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-05-15 | — | — | US | disclosed |
| US-20080107608-A1 | 5-Substituted-2-Arylpyridines | GE PING | 2008-05-08 | — | — | US | disclosed |
| US-7348345-B2 | Nonnucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2008-03-25 | — | — | US | disclosed |
| WO-2008021369-A2 | TRICYCLIC COMPOUNDS AND ITS USE AS TYROSINE KINASE MODULATORS | CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080015196-A1 | Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands | NEUROGEN CORPORATION (US) | 2008-01-17 | — | — | US | disclosed |
| US-7297695-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
| US-7223778-B2 | 5-substituted-2-arylpyridines | NEUROGEN CORPORATION (US) | 2007-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119453-A1 | Bicyclic derivatives as modulators of ion channels | KCNJ2, TRPV1, KCNN3 | PTGS2 961/4885CA2 192/4885PKM 2072/4885 |
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LPAR1, LPAR2, LPAR5 | PTGS2 1554/4885CA2 2116/4885PKM 2072/4885 |
| US-20220112176-A1 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | GABRE, GRIN2C, GRIN2A | PTGS2 2713/4885CA2 1230/4885PKM 1734/4885 |
| US-20190077793-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | PTGS2 1960/4885CA2 257/4885PKM 501/4885 |
| US-20090012117-A1 | Bicyclic derivatives as modulators of ion channels | CACNA1C, CACNA1B, CACNA1D | PTGS2 1337/4885CA2 289/4885PKM 2958/4885 |
| US-20170349566-A1 | AN EFFICIENT PROCESS FOR THE SYNTHESIS OF ALKOXY SUBSTITUTED BENZALDEHYDES | HRH4, HAAO, HRH1 | PTGS2 1299/4885CA2 2872/4885PKM 1521/4885 |
| US-20170334819-A1 | A MILD CATALYTIC REDUCTION OF C-O BONDS AND C=O BONDS USING A RECYCLABLE CATALYST SYSTEM | CBR1, ADH1C, AOC2 | PTGS2 2574/4885CA2 1258/4885PKM 2577/4885 |
| US-20080015196-A1 | Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands | CRHR1, CRHR2, CRHBP | PTGS2 3533/4885CA2 4183/4885PKM 1111/4885 |
| US-20080107608-A1 | 5-Substituted-2-Arylpyridines | CRHR2, CRHR1, HTR2C | PTGS2 2271/4885CA2 4600/4885PKM 925/4885 |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | PTGS2 696/4885CA2 1773/4885PKM 1164/4885 |
| US-20080113990-A1 | Biphenyl derivatives as modulators of voltage gated ion channels | TRPV1, TRPA1, TRPV2 | PTGS2 428/4885CA2 636/4885PKM 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.